- Details
- E David Crawford interviews Jason Efstathiou about the PARTIQoL trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. The trial, involving 450 patients from 29 centers, focuses on patient-reported outcomes, particularly bowel function at 24 months. Dr. Efstathiou presents the study's design, methodology, and key findings. The results show no significant diff...
|
- Details
- Ruchika Talwar interviews David Friedlander about a primer on healthcare performance measurement developed in conjunction with the American Urological Association. Dr. Friedlander outlines five key takeaways from the document, including the purpose of performance measurement, categories and types of measures, contexts for their use, the measurement life cycle, and advanced topics. They discuss the...
|
- Details
- In this conversation, Fred Saad discusses the PEACE-3 trial results. The study compares enzalutamide plus radium-223 versus enzalutamide alone in metastatic castration-resistant prostate cancer patients with bone metastases. Dr. Saad discusses the trial's design, highlighting significant improvements in radiographic progression-free survival and overall survival with the combination therapy. They...
|
- Details
- Jason Efstathiou about the results of the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. Dr. Efstathiou reveals that the study found no significant differences in tumor control or patient-reported quality of life between the two treatment modalities for low and intermediate-risk prostate cancer patients. He emphasizes the importance of this f...
|
- Details
- Nicholas James and Minal Padden-Modi discuss the STAMPEDE2 trial Arm P, which examines the use of upfront accelerated lutetium-PSMA-617 in metastatic hormone-sensitive prostate cancer. Dr. Padden-Modi outlines the trial design, which randomizes patients to standard of care with or without lutetium-PSMA-617, administered in an accelerated schedule. The trial includes an imaging sub-study to evaluat...
|
- Details
- Zach Klaassen interviews Michiel Van der Heijden about the SunRISe-1 trial, which evaluates TAR-200 with or without cetrelimab in BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Dr. Van der Heijden discusses the trial design and results, highlighting TAR-200 monotherapy's impressive complete response rate of 83.5% and 12-month complete response rate of 57%. He emphasizes the favorab...
|
- Details
- Duncan Gilbert discusses the PATCH trial, comparing transdermal estradiol with LHRH agonists for androgen suppression in non-metastatic prostate cancer. Dr. Gilbert discusses the trial design, which randomized 1,360 men to receive either transdermal estradiol patches or LHRH analogues. The primary results show non-inferiority of transdermal estradiol for metastasis-free survival and overall surviv...
|
- Details
- Vincenza Conteduca discusses the RAPSON trial, which compares treatment sequencing of radium-223 and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on androgen receptor pathway inhibitors. Dr. Conteduca discusses the trial design, which randomizes patients to receive either radium-223 followed by docetaxel or vice versa. The primary endpoint is ch...
|
- Details
- Neeraj Agarwal interviews Fred Saad about the Phase III ARANOTE trial. The study investigates darolutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer. Dr. Saad discusses the trial's design, patient demographics, and key findings. The results show significant improvements in radiographic progression-free survival, time to mCRPC, pain progression, and PSA respon...
|
- Details
- Ruchika Talwar interviews David Morris about changes in 2025 for Medicare Part D resulting from the Inflation Reduction Act (IRA). Dr. Morris discusses how these changes benefit prostate cancer patients and all Medicare recipients who have Medicare Part D coverage. This Medicare change reduces the out-of-pocket expenses for prescription drugs paid by Part D plans. Key points include the introducti...
|
